Ruben A. Mesa, MD, provides an update on the COMFORT-1 trial, which found that ruxolitinib has durable efficacy and long-term safety in patients with myelofibrosis.
COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis
Recent Articles
Individual Testing Effective, But Timely and Costly, in Screening for Zika Virus in Blood...
In March 2016, approximately one year after Zika virus (ZIKV) infections were reported in the United States, the U.S. Food and Drug Administration (FDA)...
Refining Patient-Doctor Communication
Refining the patient-doctor relationship became a focus early on in my career. Unlike many of my colleagues in academic hematology and oncology, I also...
Burnout? What Burnout?
Much has been written in the pages of ASH Clinical News about the Orwellian nature of modern clinical trials, and for good reason: Almost...
Hemophilia Drug Receives Priority Review From FDA
The U.S. Food and Drug Administration (FDA) has granted priority review to Roche’s biosimilar for emicizumab, a monoclonal antibody to treat children and adults...
Layoffs Suggest Deeper Problems Within Watson Health
Watson Health, an IBM project, cut staff from recently acquired data companies Explorys, Phytel, and Truven Health Analytics in an extensive round of layoffs...
Current Issue
June 2018, Volume 4, Issue 7
This issue features a look at gaining oral parity for cancer medications, the unavoidable "bubbles" in which people live and work, and more.
